Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi ...

The NWRF announced that USA Waste & Recycling and All American Waste as the first services companies to donate to the ...

The latest update is out from Monte Rosa Therapeutics ( (GLUE) ).

While we wait patiently for this upside, CUBE is paying us a 5.7%-yielding dividend. Between the yield, low- to ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (4 of 4 patients) and a 100% disease control rate, ...

Investing.com -- Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 3.5% after the company announced positive interim data from its Phase 1/2 clinical study of MRT-2359 in combination with enzalutamide ...

In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate ...

Pre-biopsy MRIs can help doctors diagnose and treat prostate cancer more accurately. Here’s when you should get one.

EPA administrator Lee Zeldin divulged that he had skin cancer removed from his face, urging people to use sunscreen and have ...

For Filipino consumers, that is what meaningful digital transformation should deliver: a future that is dynamic, secure, and has the public’s trust” ...

Common scams include impersonating law enforcement, demanding payment for fake warrants, and targeting families of ...